about
Contrast-enhanced ultrasonography in nodular splenomegaly associated with type B Niemann-Pick disease: an atypical hemangioma enhancement patternCorrespondence between salivary proteomic pattern and clinical course in primary Sjögren syndrome and non-Hodgkin's lymphoma: a case reportProgressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature.Phenobarbital-associated bone marrow aplasia: a case report and review of the literature.Hyperbaric oxygen therapy in BKV-associated hemorrhagic cystitis refractory to intravenous and intravesical cidofovir: case report and review of literature.Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.Discordant lymphoma consisting of splenic mantle cell lymphoma and marginal zone lymphoma involving the bone marrow and peripheral blood: a case report.PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells.Ultrasound findings guided a successful hemicolectomy in a leukemic patient with neutropenic enterocolitis.Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL).MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma.Preemptive valganciclovir for cytomegalovirus infection in hematological patients.Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.Vorinostat interferes with Wnt and NF-kappaB pathways in the M-07e cell line.Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells.Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure.Other mechanisms to explain the role of reduced folate carrier in cancer.MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine.Hypercytokinemia-induced metabolic encephalopathy in a multiple myeloma patient on hemodialysis undergoing autologous stem cell transplantation: clinical response after plasma exchange.Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.Platelet-derived growth factor beta receptor (PDGFRB) gene is rearranged in a significant percentage of myelodysplastic syndromes with normal karyotype.Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell linesReduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemiaTransitory marrow aplasia during Imatinib therapy in a patient with chronic myeloid leukemiaResponse to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphismsMDR1 pump: more than a drug transporter comment on "Regulatory polymorphisms of multidrug resistance 1 (MDR1) gene are associated with the development of childhood acute lymphoblastic leukaemia" by Hattori et al. [Leuk. Res. (in press)]MDR1 diplotypes as prognostic markers in multiple myelomaUnusual association of endometrial cancer and multiple myelomaMDR1 modulates apoptosis in CD34+ leukemic cellsRituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-upVascular endothelial growth factor polymorphisms in mantle cell lymphomaOutcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphismsWT1 expression levels at diagnosis could predict long-term time-to-progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromesPegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patientsFatal ongoing human cytomegalovirus reactivation during high-dose melphalan and autologous stem cell transplantationCould age modify the effect of genetic variants in IL6 and TNF-α genes in multiple myeloma?CD23 expression in plasma cell leukaemiaHigh-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institutionIn Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalentLow low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study
P50
Q30458366-C0275D55-0CEA-4090-BF41-51207C6111EBQ35570430-C6D51C9D-AAC5-43A6-9D3C-5DB3582ADF24Q37026750-BA79B351-42A8-400D-BD08-04981BB16AB2Q37071549-0F3F73E3-879B-441F-922B-3181EE72D6FFQ37227215-5D3916D9-7824-446D-A0F7-ECD62A1A09C7Q38343983-A6624934-6DD4-4AC7-8E9A-C868F35C0CD7Q38663435-23FE729E-D1B0-4403-9EE3-6DE1F791EFE3Q40107407-C556C5FE-9B5E-4CE6-B0F4-7524179F2514Q41982213-AA2B116E-81CF-403F-94B6-61C04B7CCD29Q43262235-4A61E75D-D5AA-495C-899E-6D6DB3E2B5CAQ43281107-9F3DCBAD-0CB9-4565-B226-AC402BC027DDQ44010456-A8AE2FA4-388B-4771-A5B1-6083B5E5651FQ44850006-C9FF0245-BAB4-4852-8FD6-65006B8E6A32Q45922582-33809773-FBBD-432E-9813-52E7312D06B7Q45971226-38042ACC-6E4D-4003-8E44-3A61A954EE88Q46566597-BD7102A7-ABEB-4329-813D-769BF1284693Q46808694-FB642B67-D024-4796-8A23-04A48CC03BBBQ48181306-D2E628E5-CF77-4506-8C7C-065B6FC81BE9Q48563583-58584EB7-43B0-43BD-87D2-C199F5C446E7Q54035197-D542B28F-10B0-461E-945F-6745A9219E9EQ54720518-EE65080B-9916-474C-A551-8C0C758823CCQ61952100-E4F32437-5C9F-45DD-8ED1-CB995DC9E9F2Q80070167-89B290DD-E90B-4C85-8BB9-FD274D2FAB4CQ80217502-C18AD06A-DFDC-49FB-9D79-C695952921DCQ80355511-E3EE54BB-35F8-4AA8-B5DD-4F4EC2780C65Q80865095-ED67AD5A-71D2-4C3D-9881-DFBE635F397CQ81072152-3731EFEB-CCE8-4B08-B590-FA13700C10F8Q81502054-61BA3FCA-142A-49B4-A8D5-226C030170C5Q81646168-4F3D85C4-EEA3-4ADA-9AE5-B9AB105F5A04Q81796916-13D9EFE5-845C-467D-B5A2-DF8D57105FEBQ82317528-903E771B-A85D-4F7D-8B78-7EB9B2BB7ED7Q82411516-E0726DAB-7DD7-451A-B8FF-23E21FD098C3Q82564645-C1302F05-AE36-4D08-93A2-2B6A84FB9044Q83011612-A8513075-25BA-4123-A733-F1A273A675D8Q83554087-1EEA6C85-65DF-4E91-9FD6-4D7A70F515F9Q83565381-0A01B320-529E-4598-A5F9-F599077B055EQ84567409-201DC890-412D-43FB-A825-391B17AB4B2FQ84785791-BE4023F6-8B5C-4CB0-87DB-4CBAAE8C5865Q90598642-D7BBF550-5EE1-4FFD-B92C-EC5AE8280149Q96230782-1A9E5D1E-7331-4228-B2F0-5EB408A63FEE
P50
description
researcher ORCID ID = 0000-0002-4620-0038
@en
wetenschapper
@nl
name
Sara Galimberti
@ast
Sara Galimberti
@en
Sara Galimberti
@es
Sara Galimberti
@nl
type
label
Sara Galimberti
@ast
Sara Galimberti
@en
Sara Galimberti
@es
Sara Galimberti
@nl
prefLabel
Sara Galimberti
@ast
Sara Galimberti
@en
Sara Galimberti
@es
Sara Galimberti
@nl
P106
P1153
22134275700
P21
P31
P496
0000-0002-4620-0038